Which imaging modalities are replacing nuclear scintigraphy for cancer staging and why?

• A. PET-CT due to metabolic imaging
• B. CT or MRI due to superior resolution and not limited by tissue superimposition
• C. Ultrasound due to portability
• D. Plain radiographs due to accessibility

Answer: (B)

The key idea is that precise anatomical detail from cross-sectional imaging is taking over for cancer staging in place of older functional scans. Nuclear scintigraphy shows areas of tracer uptake and can indicate where disease activity is, but its spatial resolution is limited and overlapping tissues on the image can obscure or mislocalize lesions. CT and MRI, with their cross-sectional, three-dimensional views and superb resolution, reveal the exact location and extent of tumors and metastases, helping clinicians see invasion of adjacent structures and differentiate tumor from normal tissues. CT with contrast quickly surveys large areas with good anatomic detail; MRI offers superior soft tissue contrast for brain, spine, liver, and musculoskeletal involvement. This combination provides more accurate staging and informs treatment planning, which is why they’re favored over planar nuclear scintigraphy for this purpose. While metabolic imaging like PET-CT is increasingly used in oncology, the fundamental advantage cited here is the superior anatomical detail and localization provided by CT or MRI. Ultrasound and plain radiographs, though useful in specific contexts, lack the comprehensive staging capability due to limited field of view, sensitivity, and depth of information.